Cogent Biosciences, Inc. (COGT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - The presentation is part of the 44th Annual JPMorgan Healthcare Conference, featuring Cogent Biosciences and its CEO, Andy Robbins [1] - The focus of the discussion is on the future of Cogent, particularly looking ahead to developments in 2026 and beyond [3] Company Overview - Cogent's lead asset, bezuclastinib, is a potent and selective KIT mutant inhibitor [3] - In 2025, Cogent reported positive results from three pivotal trials for bezuclastinib, marking a significant year for the company and its patients [3]